Clareo Health | A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ono Pharma USA Inc
Age
18–65
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Female 18-65 years of age (inclusive)
2. Diagnosed with IBS based on the following criteria (Rome III criteria):
* Symptom onset at least 6 months prior to diagnosis, and
* Recurrent abdominal pain or discomfort at least 3 days per month for the past 3 months, and
* Abdominal discomfort or pain associated with two or more of the following at least 25% of the time:
1. Improvement with defecation
2. Onset associated with a change in frequency of stool/defecation
3. Onset associated with a change in form (appearance) of stool
3. Diagnosed with IBS-D, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤ 25% of defecations
You may not be if
Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis or gastritis)
History of Crohn's disease, ulcerative colitis, diabetes mellitus, lactose malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that may impact the assessment of IBS symptoms
